Satellos Bioscience Future Growth
Future criteria checks 0/6
Satellos Bioscience's earnings are forecast to decline at 17.1% per annum. EPS is expected to decline by 0.1% per annum.
Key information
-17.1%
Earnings growth rate
-0.1%
EPS growth rate
| Biotechs earnings growth | 43.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Sep 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -31 | N/A | -27 | 2 |
| 12/31/2025 | N/A | -26 | N/A | -22 | 2 |
| 12/31/2024 | N/A | -25 | N/A | -22 | 2 |
| 6/30/2024 | N/A | -23 | -22 | -22 | N/A |
| 3/31/2024 | N/A | -21 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -16 | -15 | -15 | N/A |
| 9/30/2023 | N/A | -14 | -10 | -10 | N/A |
| 6/30/2023 | N/A | -13 | -8 | -8 | N/A |
| 3/31/2023 | N/A | -11 | -5 | -5 | N/A |
| 12/31/2022 | N/A | -11 | -6 | -6 | N/A |
| 9/30/2022 | N/A | -9 | -6 | -6 | N/A |
| 6/30/2022 | N/A | -18 | -7 | -7 | N/A |
| 3/31/2022 | N/A | -17 | -7 | -7 | N/A |
| 12/31/2021 | N/A | -16 | -5 | -5 | N/A |
| 9/30/2021 | N/A | -13 | -5 | -5 | N/A |
| 6/30/2021 | 0 | -2 | -2 | -2 | N/A |
| 3/31/2021 | N/A | -2 | -1 | -1 | N/A |
| 12/31/2020 | N/A | -2 | -2 | -2 | N/A |
| 12/31/2019 | 0 | -2 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MSCL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MSCL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MSCL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if MSCL's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: MSCL is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MSCL's Return on Equity is forecast to be high in 3 years time